Haemonetics Corporation Stock News

Haemonetics' (HAE) TEG testing gives vital information that can assist doctors with better control of their patients' hemostasis.

BOSTON , April 4, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, ann

BOSTON , April 1, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, h

After reaching an important support level, Haemonetics (HAE) could be a good stock pick from a technical perspective. HAE surpassed resistance at the 200-day moving average, suggesting a long-term bul

After reaching an important support level, Haemonetics (HAE) could be a good stock pick from a technical perspective. HAE surpassed resistance at the 50-day moving average, suggesting a short-term bul

Haemonetics' (HAE) acquisition of the privately held Attune Medical is likely to add the pioneering ensoETM device to its EP portfolio.

Haemonetics (HAE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Investors with an interest in Medical - Products stocks have likely encountered both Haemonetics (HAE) and Stryker (SYK). But which of these two companies is the best option for those looking for unde

BOSTON , Feb. 21, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 45th A

BOSTON , Feb. 21, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at Citi's 2024 Unplugged Me

Haemonetics' (HAE) proprietary technology, Persona, continues to gain momentum in the third quarter.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Haemonetics Corporation (HAE) Q3 2024 Earnings Call Transcript

Although the revenue and EPS for Haemonetics (HAE) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall S

Haemonetics (HAE) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $0.85 per share a year ago.